Research programme: Huntington's disease therapeutics - CHDI/Ionis Pharmaceuticals/KineMed

Drug Profile

Research programme: Huntington's disease therapeutics - CHDI/Ionis Pharmaceuticals/KineMed

Alternative Names: ISIS 387898; ISIS 388241; ISIS 408737

Latest Information Update: 24 Dec 2015

Price : $50

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Ionis Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Huntington's disease

Most Recent Events

  • 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
  • 19 May 2014 CHDI and KineMed extend their collaboration for Huntington's disease therapeutics
  • 21 Feb 2013 KineMed, Isis and CHDI are collaborating to develop companion biomarkers for antisense therapeutics in Huntingdon's disease in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top